RADIOTHERAPY OF MUCOSAL AND CUTANEOUS EPIDEMIC KAPOSI'S SARCOMA (EKS): A REPORT ON 285 PATIENTS (MEETING ABSTRACT) NLM AIDSLINE Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


RADIOTHERAPY OF MUCOSAL AND CUTANEOUS EPIDEMIC KAPOSI'S SARCOMA (EKS): A REPORT ON 285 PATIENTS (MEETING ABSTRACT)

Proc Annu Meet Am Soc Clin Oncol; 10:A1 1991. Unique Identifier : AIDSLINE ICDB/91671487
Geara F; Le Bourgeois JP; Lepechoux C; Piedbois P; Pavlovich JM; Mazeron JJ; Departement de Cancerologie, Hopital Henri Mondor, 51 Ave De; Lattre De Tassigny, 94000 Creteil, France

Abstract: Between June 1986 and October 1990, we treated 285 patients (pts) by radiotherapy for AIDS-related EKS. According to Mitsayasu's staging, 59 pts (21%) had Stage I disease, 140 (49%) Stage II, 5 (2%) Stage III and 81 (28%) Stage IV. Of the 285 pts, 30 were treated for mucosal EKS in the head and neck region (group 1), and 255 for cutaneous EKS only (group 2). The treatment schedules were as follows: 15 Gy in 10 fractions over 2 wk (group 1), or 20 Gy in 8 fractions over 2 wk followed by a 2-wk planned treatment interruption, then by a 10 Gy boost in 4 fractions over 1 wk (group 2). Pts were treated using 4-MV photons only (group 1), or using various combinations of 4-, 8-MeV electrons, 4-MV photons, or 45-kVp x-rays, depending on the site treated and on the extent of the disease (group 2). Antifungal prophylaxis using Triflucan and Fungizone, was administered 10 days before, during, and 10 days after treatment for pts in group 1. All 30 pts in group 1 achieved at least a partial response, including significant symptom relief. Of the 225 evaluable pts in group 2, 205 (91%) achieved an objective response to therapy (CR = 60%, PR = 31%). In group 1, all pts experienced grade III mucositis which usually resolved in 2 to 3 wk, but no pt developed a mucosal fungal infection secondary to treatment. In group 2, 14 (6%) pts experienced severe epidermitis with some necrosis, 62 (28%) exudative epidermitis, 129 (57%) dry epidermitis, and 20 (9%) varying degrees of erythema. We conclude that radiotherapy is useful and can be recommended as a palliative treatment to relieve pain and physical discomfort or to improve cosmetic appearance in pts with cutaneous EKS. We also conclude that irradiation for mucosal EKS is quite effective and is without risk of major complications when administered with adequate antifungal prophylaxis.
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Comparative Study Human Neoplasm Staging Palliative Care Radiotherapy/ADVERSE EFFECTS Radiotherapy Dosage Retrospective Studies Sarcoma, Kaposi's/ETIOLOGY/PATHOLOGY/*RADIOTHERAPY Skin Neoplasms/ETIOLOGY/PATHOLOGY/*RADIOTHERAPY ABSTRACT CLINICAL TRIALKWDacquiredimmunodeficiencysyndrome/KWDcomplicationscomparativestudyhumanneoplasmstagingpalliativecareradiotherapy/adverseeffectsradiotherapydosageretrospectivestudiessarcoma,kaposi's/etiology/pathology/KWDradiotherapyskinneoplasms/etiology/pathology/KWDradiotherapyabstractclinicaltrial
910930
M9190727

Copyright © 1991 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .